Nothing Special   »   [go: up one dir, main page]

AR118720A1 - Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 - Google Patents

Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3

Info

Publication number
AR118720A1
AR118720A1 ARP200101091A ARP200101091A AR118720A1 AR 118720 A1 AR118720 A1 AR 118720A1 AR P200101091 A ARP200101091 A AR P200101091A AR P200101091 A ARP200101091 A AR P200101091A AR 118720 A1 AR118720 A1 AR 118720A1
Authority
AR
Argentina
Prior art keywords
psma
antibody
sec
prostate cancer
binding domain
Prior art date
Application number
ARP200101091A
Other languages
English (en)
Inventor
Hong Xie
Shoba Shetty
Theresa Mdevitt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR118720A1 publication Critical patent/AR118720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Un método para tratar cáncer de próstata en un paciente, el método comprende administrar al paciente una cantidad segura de un fragmento de anticuerpo anti-PSMAxCD3, en donde el anticuerpo anti-PSMA x CD3 comprende un primer dominio de unión que se une específicamente a PSMA y un segundo dominio de unión que se une específicamente a CD3, en donde el primer dominio de unión comprende una cadena pesada (HC) de la sec. con núm. de ident.: 7 y una cadena ligera (LC) de la sec. con núm. de ident.: 8 y el segundo dominio de unión comprende una cadena pesada (HC) de la sec. con núm. de ident.: 17 y una cadena ligera (LC) de la sec. con núm. de ident.: 18.
ARP200101091A 2019-04-19 2020-04-17 Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 AR118720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962836270P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
AR118720A1 true AR118720A1 (es) 2021-10-27

Family

ID=70465163

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101091A AR118720A1 (es) 2019-04-19 2020-04-17 Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3

Country Status (13)

Country Link
US (1) US11591395B2 (es)
EP (1) EP3956022A1 (es)
JP (1) JP2022529985A (es)
KR (1) KR20220002899A (es)
CN (1) CN113747944A (es)
AR (1) AR118720A1 (es)
AU (1) AU2020259404A1 (es)
BR (1) BR112021020532A2 (es)
CA (1) CA3136888A1 (es)
MA (1) MA55717A (es)
MX (1) MX2021012767A (es)
TW (1) TW202104265A (es)
WO (1) WO2020212947A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022162518A2 (en) * 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2023164510A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
WO2023224912A1 (en) * 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
ES2152483T3 (es) 1992-11-13 2001-02-01 Idec Pharma Corp Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
SI0973804T1 (sl) 1997-04-07 2007-06-30 Genentech Inc Proti-VEGF protitelesa
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
DK1538206T3 (da) 1997-09-16 2010-07-12 Centocor Ortho Biotech Inc Fremgangsmåde til fuldstændig kemisk syntese og samling af gener og genomer
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
PT1482932E (pt) 2002-03-13 2010-01-12 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
RS20170595A1 (sr) 2003-05-30 2017-09-29 Genentech Inc Tretman sa anti-vegf antitelima
DE602004025101D1 (de) 2003-05-31 2010-03-04 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005048935A2 (en) 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007004415A1 (ja) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
EP2222675B1 (en) 2007-12-19 2013-09-11 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
KR101820535B1 (ko) * 2008-10-01 2018-01-19 암젠 리서치 (뮌헨) 게엠베하 종간특이적 ｐｓｍａｘｃｄ3 이중특이적 단일쇄 항체
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5719354B2 (ja) 2009-05-27 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三重又は四重特異性抗体
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
CA2893505C (en) 2012-11-21 2023-02-21 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
CN106414497B (zh) 2014-05-29 2021-07-27 宏观基因有限公司 三特异性结合分子和其使用方法
SG11201701599UA (en) 2014-09-05 2017-03-30 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
CA2985138A1 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
JP7019423B2 (ja) 2015-05-06 2022-02-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11202004906QA (en) * 2017-12-18 2020-07-29 Janssen Biotech Inc Radiolabeling of polypeptides
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
KR20210012007A (ko) 2018-05-24 2021-02-02 얀센 바이오테크 인코포레이티드 항-cd3 항체 및 이의 용도
KR20210015902A (ko) * 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
WO2020212949A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody

Also Published As

Publication number Publication date
MX2021012767A (es) 2021-11-18
CA3136888A1 (en) 2020-10-22
KR20220002899A (ko) 2022-01-07
CN113747944A (zh) 2021-12-03
MA55717A (fr) 2022-02-23
TW202104265A (zh) 2021-02-01
US11591395B2 (en) 2023-02-28
AU2020259404A1 (en) 2021-09-23
WO2020212947A1 (en) 2020-10-22
US20210040209A1 (en) 2021-02-11
BR112021020532A2 (pt) 2022-03-15
JP2022529985A (ja) 2022-06-27
EP3956022A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AR118720A1 (es) Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
ECSP17005649A (es) Anticuerpos anti-tau humanizados
PE20241349A1 (es) Anticuerpos de union a cd3
BR112016013896A2 (pt) métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
CR20120454A (es) Proteínas terapéuticas de unión a dll4
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
PE20241170A1 (es) Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
CR10325A (es) Diagnosticos y tratamientos para tumores
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
AR083747A1 (es) Anticuerpos anti-il-23
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
MX2009013327A (es) Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2022002244A (es) Metodo para identificar respondedores a degradantes de smarca2/4.
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple
AR118721A1 (es) Métodos para tratar el cáncer renal con un anticuerpo anti-psma / cd3
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
AR118353A1 (es) Métodos para producir composiciones de anticuerpos anti-tnf
AR118354A1 (es) Métodos para producir composiciones de anticuerpos anti-tnf